A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Completed · Phase 1 · Has a placebo group

Conditions studied: Chronic Genotype 1 Hepatitis C Virus Infection

In brief

The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.

Key facts

Study ID

NCT01247194

Run by

Presidio Pharmaceuticals, Inc.

People needed

24

Starts

2010-10-01

Expected to finish

2011-06-01

Last updated by the study team

2012-02-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Local Institution — Sacramento, California, United States
• Local institution — San Francisco, California, United States
• Local institution — Aarhus, Denmark
• Local institution — Copenhagen, Denmark
• Local institution — Herlev, Denmark
• Local institution — Hvidovre, Denmark
• Local institution — Kolding, Denmark
• Local institution — Odense, Denmark
• Local institution — London, United Kingdom
• Local institution — London, United Kingdom
• Local institution — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.